Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.10 (6.25%)
Bid:
1.55
Ask:
1.85
Spread: 0.30 (19.355%)
Market Cap: £264.88k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Smart Cells Deal

22 Oct 2018 07:00

RNS Number : 6821E
WideCells Group PLC
22 October 2018
 

22 October 2018

WideCells Group PLC ('WideCells Group' or 'the Group')

CellPlan deal with Smart Cells

 

WideCells Group PLC, the healthcare services group focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to announce that its stem cell healthcare insurance subsidiary, CellPlan, has signed a partnership agreement with a leading international stem cell extraction and storage company, Smart Cells.

 

Under the terms of the agreement, Smart Cells, which has offices in Europe, Africa, Middle East, Asia and the Far East, will offer CellPlan's innovative insurance plan to its 60,000 clients across multiple geographies. The staged roll-out will commence in Spain within the next four weeks, followed by the UK and then worldwide. With CellPlan operations already in place in Spain and the UK CellPlan can commence stem cell insurance sales soon, unlocking revenue from Smart Cell's existing and new client base.

 

WideCell's CEO, João Andrade, said, "We are delighted to be working closely with Smart Cells, which is a well-established and respected global company, to enhance its offering with our unique stem cell treatment insurance plan and increase CellPlan's own profile worldwide. This is a seminal deal for CellPlan, in line with our corporate strategy focused on building revenue growth and delivering accessible and affordable cell treatments to more people."

 

Smart Cells CEO, Shamshad Ahmed, said, "I believe that this partnership will be mutually beneficial for both companies and especially useful for our clients all over the world. I look forward to cooperating with CellPlan and working together on the global rollout of re-enhanced services." 

 

**ENDS**

 

For further information, please visit the Group's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

 

WideCells Group PLC

CEO - João Andrade

Tel: +351 919 033 171

E: shareholders@widecellsgroup.com

Shard Capital Partners LLP

Broker - Damon Heath & Erik Woolgar

Tel: +44 (0) 20 7186 9950

St Brides Partners Limited

PR - Priit Piip & Isabel de Salis

Tel: +44 (0) 20 7236 1177

 

Notes to Editors

 

WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments both accessible and affordable. This is delivered through two divisions:

· CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.

· WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.

 

Stem Cell Fast Facts:

· Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families, because it is simple, safe and painless to collect, relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of cord blood.

· Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.

· 82 illnesses can currently be treated using stem cell procedures.

· Despite initial collection and storage often costing no more than a few £thousands, actual treatment can cost in the £hundreds of thousands - before the development of an insurance product such as CellPlan, the treatment remained largely available only to Higher Net Worth individuals.

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBSBDGUBDBGIB
Date   Source Headline
2nd Jun 20265:18 pmRNSConversion of Notes and Allotment of Shares
29th May 20267:00 amRNSTotal Voting Rights
29th Apr 202612:58 pmRNSConversion of Notes and Allotment of Shares
31st Mar 20267:00 amRNSInterim Results
27th Feb 202610:23 amRNSTotal Voting Rights
23rd Feb 20267:00 amRNSConversion of Notes and Allotment of Shares
31st Dec 202511:37 amRNSResult of AGM
8th Dec 20252:16 pmRNSNotice of AGM
23rd Oct 20252:30 pmRNSFull Year Results
12th Aug 20252:04 pmRNSUpdate on Compliance with UK Listing Rules
30th Jun 20253:27 pmRNSHolding(s) in Company
30th Jun 20253:25 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNSTotal Voting Rights
9th Jun 20254:28 pmRNSConversion of Notes and Allotment of Shares
6th Jun 20259:48 amRNSConversion of Notes and Allotment of Shares
3rd Jun 20252:54 pmRNSConversion of Notes and Allotment of Shares
30th May 20254:00 pmRNSConversion of Notes and Allotment of Shares
28th May 20255:24 pmRNSConversion of Notes and Allotment of Shares
28th May 20254:54 pmRNSHolding(s) in Company
28th May 20254:52 pmRNSHolding(s) in Company
28th May 20254:50 pmRNSHolding(s) in Company
28th May 20254:48 pmRNSHolding(s) in Company
20th May 20257:30 amRNSRestoration Iconic Labs Plc
20th May 20257:00 amRNSRestoration of Trading and Funding Update
15th May 20254:18 pmRNSResult of AGM
24th Apr 20255:16 pmRNSNotice of AGM
31st Mar 20256:41 pmRNSInterim Results
31st Mar 20255:26 pmRNSRevised Results for the Year ended 30 June 2024
13th Feb 20255:55 pmRNSTransaction Terminated
7th Feb 20252:52 pmRNSNotification of Major Holdings
31st Oct 20243:57 pmRNSFull Year Results for the Year ended 30 June 2024
9th Sep 20247:00 amRNSWaiver of Event of Default
10th Jul 20244:22 pmRNSBoard Changes
28th Mar 20247:00 amRNSInterim Results
11th Mar 202412:00 pmRNSHeads of Terms Signed
29th Feb 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSSuspension of Trading
13th Feb 20242:08 pmRNSResult of AGM
7th Feb 20249:10 amRNSConversion of Notes and Allotment of Shares
19th Jan 20243:49 pmRNSNotice of AGM
4th Jan 20247:00 amRNSBoard Changes & Business and Strategy Update
29th Dec 20237:00 amRNSTotal Voting Rights
7th Dec 20238:53 amRNSConversion of Securities
4th Dec 20237:53 amRNSConversion of Securities
30th Nov 20237:00 amRNSTotal Voting Rights
17th Nov 202311:32 amRNSConversion of Securities
13th Nov 20238:40 amRNSConversion of Securities
2nd Nov 202310:35 amRNSConversion of Securities
31st Oct 20239:29 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSFull Year Results for the Year ended 30 June 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.